STEVEN L. MERRILL, M.D.; ALVIN DAVIS, M.D.; BERNARD SMOLENS, M.D.; SYDNEY M. FINEGOLD, M.D., F.A.C.P.
Cephalothin*, 7-(thiophene-2-acetamido)-cephalosporanic acid, a semisynthetic derivative of cephalosporin C, became available for clinical trial in the United States in 1962. Its history, chemistry, and early clinical use have been the subject of several recent reports (1-9).
It has been shown to be effective against penicillinase-producing staphylococci, certain other gram-positive cocci, and certain gram-negative bacilli. Some workers have speculated that there would not be cross-allergenicity between cephalothin and the penicillins, and cephalothin has been administered to patients known to be allergic to penicillin G without apparent untoward effect (5, 7, 9). Skin-reactive and hemagglutinating antibody studies in animals have
MERRILL SL, DAVIS A, SMOLENS B, et al. Cephalothin in Serious Bacterial Infection. Ann Intern Med. 1966;64:1–12. doi: https://doi.org/10.7326/0003-4819-64-1-1
Download citation file:
Published: Ann Intern Med. 1966;64(1):1-12.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use